ArticleActa biomaterialia2026
Micropatterning transcriptionally and phenotypically reprograms endothelial cells.
Article in Acta biomaterialia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Vascular occlusions are a major cause of cardiovascular disease and require interventions including graft bypass surgery; yet, the development of synthetic vascular grafts remains a challenge due to the inability of synthetic biomaterials to support an anti-immunogenic endothelium. Topographical micropatterning of biophysical cues offers a promising strategy to enhance graft endothelialization. As the interface between the biomaterial and blood, endothelial cells provide a bioactive interface which regulates inflammation. We utilized topographical micropatterning of polyurethane biomaterial to induce endothelial cell elongation and alignment and measured the resultant transcriptional changes using bulk RNA-sequencing. Cell phenotype was characterized by gene and protein expression as well as chemokine secretion. The biomaterial micropatterning-modulated elongated and aligned morphology promoted an anti-inflammatory transcriptome, reduced pro-inflammatory chemokine secretion, and induced the transcription coregulator yes-associated protein (YAP) phosphorylation, supporting the anti-immunogenic properties of endothelial cells. Cytoskeletal regulation of this anti-immunogenic phenotype was quantified through measurement of intermediate filament vimentin regulation of YAP localization and endothelial pro-immunogenic gene expression. Aggregation of vimentin was positively correlated with YAP dephosphorylation and suppressed proinflammatory gene expression, indicating that endothelial elongation and alignment influence gene regulation and cellular function independent of vimentin-mediated mechanisms. The ability of micropatterned endothelial cells to maintain their anti-immunogenic functions under pro-inflammatory conditions was demonstrated by the increased phosphorylation of YAP and decrease in pro-inflammatory IL-8 release. Our study highlights the potential of biomaterial cues to regulate endothelial cell behavior for vascular graft design. STATEMENT OF SIGNIFICANCE: We used topographical micropatterning to separate the role of endothelial monolayer morphology from unidirectional blood flow and test how architecture alone regulates gene programs. Micropatterned substrates produced a reproducibly elongated, aligned endothelium with coordinated modeling of the vimentin intermediate filament network. Bulk transcriptomics revealed a distinct morphology-associated expression state, including reduced inflammatory signaling and altered secretory profiles, alongside shifts in mechanosensitive regulatory programs and downstream transcriptional signatures. Together, these findings link cytoskeletal organization to endothelial mechanotransduction and highlight biomaterial topography as a design lever to tune endothelial function for preclinical and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.